Abstract
Proton pump inhibitors (PPIs) are recommended in patients with prior upper gastrointestinal bleeding and considered appropriate in patients with multiple other risk factors who require dual antiplatelet treatment (DAPT). During the past few years, however, concerns have been raised about the potential for PPIs, especially omeprazole, to decrease the efficacy of clopidogrel, and both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have issued warnings regarding the concomitant use of these medications. A review of the literature revealed that the pharmacodynamic studies support an interaction, whereas the clinical evidence, which is mainly based on nonrandomized, observational studies and secondary analyses of randomized trials, is conflicting. We conclude that PPIs should be prescribed together with DAPT for patients in whom they are recommended according to the guidelines and for patients with other indications. With respect to omeprazole, current evidence does not allow clear recommendations to be provided.
Keywords: Proton pump inhibitors, omeprazole, clopidogrel, CYP2C19, drug interactions.
Current Vascular Pharmacology
Title:The Clopidogrel-PPI Interaction: An Updated Mini-Review
Volume: 12 Issue: 5
Author(s): Jacob Juel, Manan Pareek and Svend Eggert Jensen
Affiliation:
Keywords: Proton pump inhibitors, omeprazole, clopidogrel, CYP2C19, drug interactions.
Abstract: Proton pump inhibitors (PPIs) are recommended in patients with prior upper gastrointestinal bleeding and considered appropriate in patients with multiple other risk factors who require dual antiplatelet treatment (DAPT). During the past few years, however, concerns have been raised about the potential for PPIs, especially omeprazole, to decrease the efficacy of clopidogrel, and both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have issued warnings regarding the concomitant use of these medications. A review of the literature revealed that the pharmacodynamic studies support an interaction, whereas the clinical evidence, which is mainly based on nonrandomized, observational studies and secondary analyses of randomized trials, is conflicting. We conclude that PPIs should be prescribed together with DAPT for patients in whom they are recommended according to the guidelines and for patients with other indications. With respect to omeprazole, current evidence does not allow clear recommendations to be provided.
Export Options
About this article
Cite this article as:
Juel Jacob, Pareek Manan and Jensen Eggert Svend, The Clopidogrel-PPI Interaction: An Updated Mini-Review, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/157016111205140926161509
DOI https://dx.doi.org/10.2174/157016111205140926161509 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Cardiac Molecular Imaging Using Positron Emission Tomography in Evaluation of Drug and Therapeutics for Cardiovascular Disorders
Current Pharmaceutical Design Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease
Current Pharmaceutical Design MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Oxidative Stress Targeting Amyloid Beta Accumulation and Clearance in Alzheimer’s Disease: Insight into Pathological Mechanisms and Therapeutic Strategies
Current Psychopharmacology Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Advances in Drug Safety
Current Pharmaceutical Design CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design A Systemic Review of Adult Mesenchymal Stem Cell Sources and their Multilineage Differentiation Potential Relevant to Musculoskeletal Tissue Repair and Regeneration
Current Stem Cell Research & Therapy Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Predictors of “Worsening Renal Function” in Patients Hospitalized in Internal Medicine Department
Current Drug Safety The Relationship Between Inflammation, Platelet Activation and Antiplatelet Resistance
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Primary Heart Involvement in Systemic Sclerosis
Current Rheumatology Reviews Lipid Peroxidation End-Products as Modulators of Catabolic and Inflammatory Responses in Arthritis: A Review
Current Rheumatology Reviews